Glycomics Market: Anticipating a $3.7 Billion Market by 2027 - Exclusive Report by MarketsandMarkets™

glycomics/glycobiology market is projected to reach USD 3.7 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 15.5% during the forecast period.

Glycobiology is the study of carbohydrates (glycans) and their roles in various biological processes, including cell-cell communication, cell adhesion, immune response, and more. This field has gained significant attention due to its potential implications for understanding diseases and developing therapeutic interventions.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132685525

glycomics/glycobiology market is projected to reach USD 3.7 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 15.5% during the forecast period. Growth in the glycomics/glycobiology market can be attributed to factors such as the collaborations and partnerships among market players for the development of glycobiology products, advanced technology for glycobiology, increasing prevalence of cancer and increased use of glycans as biomarkers to identify diseases.

The Glycobiology market includes various products, services, and research tools aimed at studying and manipulating glycans. Some key aspects of the Glycobiology market include:

Research Tools and Reagents: Companies offer a range of research tools, kits, reagents, and antibodies for studying glycans and their interactions.

Therapeutics and Drug Development: Glycobiology plays a crucial role in understanding diseases where glycan-related processes are involved, such as cancer, inflammatory disorders, and infectious diseases.

Diagnostic Applications: Glycans can serve as biomarkers for various diseases. The development of glycan-based diagnostic tools has the potential to improve disease detection, prognosis, and monitoring.

Biotechnology and Biopharmaceuticals: Glycobiology is important in the production of biopharmaceuticals and biotherapeutics, as glycosylation patterns can affect the efficacy, stability, and immunogenicity of these products.

Academic and Industrial Research: Both academic researchers and pharmaceutical/biotechnology companies are interested in glycobiology to advance our understanding of basic biology and to develop new therapies and technologies.

Market Growth and Trends: The Glycobiology market has been growing steadily, driven by advancements in glycan analysis technologies, increased awareness of the importance of glycans in health and disease, and the potential for new therapeutic targets.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132685525

Key market Players

The prominent players operating in this market include Thermo Fisher Scientific (US), New England Biolabs (US), Merck KGaA (Germany), Promega Corporation (US), Waters Corporation (US), Takara Bio Inc, (Japan), Bio-Techne (US), Agilent Technologies (US), Sumitomo Bakelite Co. Ltd. (Japan), Bruker Corporation (US), Shimadzu Corporation (Japan), Danaher Corporation (US), AMS Bio (UK), Ludger Ltd (UK), Z Biotech, LLC (US), Chemily Glycoscience (US), CD BioGlyco (US), GlycoDiag (France), Kode Biotech Limited (New Zealand), Glyxera GmBH (Germany), Lectenz Bio (US), Glycomix Ltd (UK), IEC Group (Italy), Asparia Glycomics (Spain) and Ray Biotech Life Inc. (US)

Merck KGaA is also one of the leading players in the glycomics/glycobiology market. The company focuses on inorganic growth strategies such as investment to strengthen its market position.

Thermo Fisher Scientific held the second position in the glycomics/glycobiology market. The company has entered into collaborations and partnerships with a number of life science companies to develop and promote the use of glycobiology products and is recognized for its contribution in the glycobiology space.

Agilent Technologies provides a comprehensive portfolio of chromatography systems, along with enzymes, kits, and standards in glycomics/glycobiology market.

The North America market is expected to register the highest CAGR during the forecast period. In North America, the growth of the market is driven by the increasing investments in the glycobiology research, presence of pharmaceutical and biotechnology companies and improved healthcare infrastructure.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=132685525

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]


healthcare

51 Blog posts

Comments